title: Therapy Effect: Impact on Bone Marrow Morphology.
abstract: This article highlights the most common morphologic features identified in the bone marrow after chemotherapy for hematologic malignancies, growth-stimulating agents, and specific targeted therapies. The key is to be aware of these changes while reviewing post-therapeutic bone marrow biopsies and to not mistake reactive patterns for neoplastic processes. In addition, given the development and prevalent use of targeted therapy, such as tyrosine kinase inhibitors and immune modulators, knowledge of drug-specific morphologic changes is required for proper bone marrow interpretation and diagnosis.
authors.affiliation: Hematopathology, Department of Pathology, University of Utah/ARUP Laboratories, 500 Chipeta Way, 115-G04, Salt Lake City, UT 84108, USA.
authors.forename: K David
authors.initials: KD
authors.lastname: Li
authors.affiliation: Hematopathology, Department of Pathology, University of Utah/ARUP Laboratories, 500 Chipeta Way, 115-G04, Salt Lake City, UT 84108, USA. Electronic address: mohamed.salama@path.utah.edu.
authors.forename: Mohamed E
authors.initials: ME
authors.lastname: Salama
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D001284:Atrophy / Q000139:chemically induced; D001853:Bone Marrow / Q000187:drug effects* / Q000473:pathology*; D016207:Cytokines / Q000494:pharmacology; D019337:Hematologic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate / Q000494:pharmacology; D036341:Intercellular Signaling Peptides and Proteins / Q000494:pharmacology; D000077269:Lenalidomide; D019653:Myeloablative Agonists / Q000494:pharmacology; D009336:Necrosis; D000069283:Rituximab / Q000494:pharmacology; D013792:Thalidomide / Q000031:analogs & derivatives / Q000494:pharmacology
chemical_list: D000970:Antineoplastic Agents; D016207:Cytokines; D036341:Intercellular Signaling Peptides and Proteins; D019653:Myeloablative Agonists; D000069283:Rituximab; D013792:Thalidomide; D000068877:Imatinib Mesylate; D000077269:Lenalidomide
keywords: Bone marrow; Hematologic malignancies; Post-therapy and treatment effects